Cancer Genomics and Precision Medicine: A Way Toward Early Diagnosis and Effective Cancer Treatment
Since the first draft of the Human Genome Project was completed in April 2003, biomedical researchers have been mining and extrapolating genomic data toward the goal of improving human health and realizing medical benefits. The promise of “personalized oncomedicine,” the matching of therapeutics to appropriate molecular targets in individual cancer patients, lies in the convergence of cancer researchers, computational biologist, and clinicians to identify the driving mutations involved in tumor progression and metastasis and pursue appropriate therapies. The virtual concept of “cancer genome” in the development of uncontrolled cell growth was conceived as early as late nineteenth and early twentieth century by Theodor Boveri (Boveri 2008). Boveri hypothesized that malignant tumors could be the result of a certain abnormal condition of the chromosomes arising from multipolar mitosis. Several decades later the discovery of the Philadelphia chromosome as the genetic driver of chronic myeloid leukemia (CML) provided the experimental evidence for Boveri’s hypothesis (Nowell and Hungerford 1961).
KeywordsChronic Myeloid Leukemia Transcriptome Sequencing Solitary Fibrous Tumor Polycomb Repressive Complex Fusion Transcript
We thank Jyoti Athanikar for critically reading the manuscript. B.A. is an Intermediate Fellow of the Wellcome Trust-DBT India Alliance [IA/I(S)/12/2/500635 to BA] and a Young Investigator of the DST-FAST Track scheme.
No competing interests to be disclosed.
Dr. Bushra Ateeq
Dr. Bushra Ateeq is an Assistant Professor at Department of Biological Sciences and Bioengineering (BSBE), IIT, Kanpur, India. The primary research focus of Dr. Bushra’s laboratory is to understand the complex molecular events involved in prostate and breast cancer, identify early diagnostic markers and valuable therapeutic targets. Her lab focuses on experimental evaluation of the functional relevance of the genetic rearrangements, copy number changes, and somatic alterations identified by genomic approaches, using molecular and cellular approaches.
- Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Harris H. J Cell Sci. 2008;121 Suppl 1:1–84.Google Scholar
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11.CrossRefPubMedPubMedCentralGoogle Scholar